Safe Orthopaedics announced on Monday, July 10, 2017, that sales for the second quarter 2017 rose 37% (excluding currency and acquisitions). Sales for the quarter were €880 thousand, which is up from €643 thousand reported in the second quarter of 2016.
Safe Orthopaedics Posts 37% Second Quarter Sales Increase
1 min read Premium comments
Secondary
Safe Orthopaedics, which is based in Eragny-sur-Oise, France, specializes in sterile implants and single-use instruments for spinal surgery. The following table shows the sales details for second quarter 2017.
" data-large-file="https://i0.wp.com/ryortho.com/wp-content/uploads/2017/07/Safe_2Q17_Table_WEB.jpg?fit=730%2C127&ssl=1" src="https://i0.wp.com/ryortho.com/wp-content/uploads/2017/07/Safe_2Q17_Table_WEB.jpg?resize=730%2C127&ssl=1" alt="" width="730" height="127">Source: Safe Orthopaedics company documents
According to a press release, France continued an upward trend from the first quarter with a growth of 29% in the second quarter. In the rest of the world, the 44% increase in second quarter 2017 revenue was due in part to the continued growth of sales in Mexico and Germany.
“Our second-quarter 2017 revenues demonstrate the benefits of our strategic realignment. For the third quarter in a row, we have achieved a high level of growth”, said Pierre Dumouchel, chief executive officer of Safe Orthopaedics in a press release.
He added, “To maintain this brisk pace of growth in Europe and in emerging markets, we will continue to promote the benefits of our technologies for minimally-invasive and trauma surgeries. What’s more the recent additions to our sales and marketing teams in France and Germany should unlock major growth opportunities over the next few quarters.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.